Neoadjuvant chemotherapy with FOLFOXIRI for high-risk relapsed locally advanced colon cancer: a single-arm phase II trial.

ABSTRACT:

Background

To evaluate the safety and deliverability of neoadjuvant chemotherapy (NAC) with three-drug-intensity chemotherapy [oxaliplatin, irinotecan, and fluorouracil (FOLFOXIRI)] in patients with high-risk factors for recurrence and metastasis of locally advanced colon cancer (hr-LACC).

Patients and methods

A single-arm, open-label, phase II trial was conducted at West China Hospital of Sichuan University from July 2020 to October 2023. Patients with T4a/b and/or N2/fused lymph nodes and no distant metastases were considered as the hr-LACC patients. Eligible enrolled patients received four cycles of NAC with FOLFOXIRI followed by surgery and adjuvant chemotherapy with capecitabine and oxaliplatin (CAPOX) for two to five cycles or single-agent capecitabine for five cycles

SUBMITTER: Zhou YW 

PROVIDER: S-EPMC12529308 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature